Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Disseminated Intravascular Coagulation | 4 | 2022 | 14 | 2.810 |
Why?
|
Blood Coagulation Tests | 8 | 2022 | 23 | 2.780 |
Why?
|
Automation, Laboratory | 3 | 2020 | 13 | 1.970 |
Why?
|
Blood Coagulation | 6 | 2022 | 29 | 1.740 |
Why?
|
Anticoagulants | 5 | 2020 | 51 | 1.630 |
Why?
|
Hemostatics | 2 | 2022 | 17 | 1.560 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 2 | 2022 | 7 | 1.490 |
Why?
|
Humans | 53 | 2024 | 14077 | 1.450 |
Why?
|
Clinical Laboratory Techniques | 3 | 2019 | 56 | 1.400 |
Why?
|
Enoxaparin | 2 | 2020 | 11 | 1.390 |
Why?
|
Quality Assurance, Health Care | 2 | 2019 | 43 | 1.290 |
Why?
|
Point-of-Care Systems | 2 | 2020 | 88 | 1.280 |
Why?
|
Fibrin Fibrinogen Degradation Products | 5 | 2024 | 19 | 1.260 |
Why?
|
HIV Infections | 9 | 2023 | 4946 | 1.250 |
Why?
|
Cardiovascular Diseases | 2 | 2023 | 235 | 1.190 |
Why?
|
von Willebrand Factor | 6 | 2024 | 21 | 1.150 |
Why?
|
von Willebrand Diseases | 3 | 2022 | 8 | 1.060 |
Why?
|
Hematology | 1 | 2024 | 4 | 0.930 |
Why?
|
Hemoglobins | 2 | 2022 | 40 | 0.920 |
Why?
|
Quality Control | 3 | 2020 | 27 | 0.890 |
Why?
|
Thrombotic Microangiopathies | 1 | 2022 | 5 | 0.840 |
Why?
|
Venous Thromboembolism | 3 | 2019 | 26 | 0.830 |
Why?
|
Virus Diseases | 2 | 2023 | 55 | 0.830 |
Why?
|
Female | 24 | 2024 | 8751 | 0.820 |
Why?
|
International Normalized Ratio | 3 | 2018 | 17 | 0.800 |
Why?
|
Male | 24 | 2024 | 6489 | 0.800 |
Why?
|
Tertiary Care Centers | 2 | 2022 | 78 | 0.780 |
Why?
|
South Africa | 25 | 2022 | 7312 | 0.780 |
Why?
|
Platelet Activation | 1 | 2021 | 17 | 0.780 |
Why?
|
Surveys and Questionnaires | 5 | 2019 | 532 | 0.760 |
Why?
|
Freezing | 1 | 2020 | 6 | 0.750 |
Why?
|
Factor Xa Inhibitors | 1 | 2020 | 3 | 0.750 |
Why?
|
Coronavirus | 1 | 2021 | 14 | 0.740 |
Why?
|
Anemia | 1 | 2020 | 41 | 0.710 |
Why?
|
Reproducibility of Results | 5 | 2024 | 210 | 0.700 |
Why?
|
Plasma Exchange | 1 | 2019 | 2 | 0.670 |
Why?
|
Hemostasis | 1 | 2019 | 15 | 0.670 |
Why?
|
Immunoturbidimetry | 1 | 2019 | 3 | 0.660 |
Why?
|
Blood Chemical Analysis | 1 | 2019 | 14 | 0.660 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2019 | 4 | 0.650 |
Why?
|
Lipid Metabolism | 1 | 2019 | 44 | 0.640 |
Why?
|
Drug Monitoring | 2 | 2018 | 55 | 0.630 |
Why?
|
Warfarin | 1 | 2018 | 15 | 0.620 |
Why?
|
Retrospective Studies | 4 | 2022 | 767 | 0.620 |
Why?
|
Middle Aged | 17 | 2024 | 3425 | 0.610 |
Why?
|
Academic Medical Centers | 1 | 2018 | 29 | 0.610 |
Why?
|
Respiratory Tract Infections | 1 | 2021 | 251 | 0.600 |
Why?
|
Thrombosis | 5 | 2024 | 47 | 0.590 |
Why?
|
Specimen Handling | 1 | 2018 | 103 | 0.590 |
Why?
|
Anti-Retroviral Agents | 2 | 2019 | 542 | 0.550 |
Why?
|
Adult | 19 | 2024 | 5664 | 0.520 |
Why?
|
Risk Factors | 7 | 2024 | 1431 | 0.500 |
Why?
|
Biomarkers | 4 | 2023 | 322 | 0.460 |
Why?
|
Blood Platelets | 2 | 2022 | 30 | 0.390 |
Why?
|
Venous Thrombosis | 2 | 2010 | 14 | 0.390 |
Why?
|
Laboratories | 2 | 2024 | 44 | 0.390 |
Why?
|
ADAMTS13 Protein | 2 | 2022 | 7 | 0.380 |
Why?
|
Fibrinogen | 2 | 2022 | 10 | 0.360 |
Why?
|
Prothrombin Time | 2 | 2022 | 15 | 0.360 |
Why?
|
HIV | 2 | 2023 | 380 | 0.340 |
Why?
|
Pandemics | 2 | 2021 | 280 | 0.310 |
Why?
|
Prevalence | 5 | 2019 | 1149 | 0.300 |
Why?
|
Asthma | 4 | 1995 | 33 | 0.300 |
Why?
|
Aged | 10 | 2018 | 1650 | 0.280 |
Why?
|
Hemorrhage | 2 | 2018 | 70 | 0.250 |
Why?
|
Blood Cell Count | 2 | 2024 | 15 | 0.250 |
Why?
|
Altitude | 1 | 2024 | 9 | 0.240 |
Why?
|
Japan | 1 | 2024 | 7 | 0.230 |
Why?
|
Leukocyte Count | 1 | 2024 | 24 | 0.230 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 44 | 0.220 |
Why?
|
Interleukin-6 | 1 | 2023 | 50 | 0.210 |
Why?
|
Aged, 80 and over | 4 | 2018 | 449 | 0.210 |
Why?
|
Lactate Dehydrogenases | 1 | 2022 | 4 | 0.210 |
Why?
|
Hemolysis | 1 | 2022 | 7 | 0.210 |
Why?
|
Spirometry | 3 | 1998 | 12 | 0.210 |
Why?
|
Acute-Phase Proteins | 1 | 2022 | 14 | 0.210 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2019 | 124 | 0.210 |
Why?
|
Time Factors | 4 | 2018 | 503 | 0.200 |
Why?
|
Cytokines | 1 | 2023 | 107 | 0.200 |
Why?
|
Mean Platelet Volume | 1 | 2021 | 3 | 0.200 |
Why?
|
Platelet Count | 1 | 2021 | 14 | 0.200 |
Why?
|
Pilot Projects | 3 | 2019 | 168 | 0.190 |
Why?
|
Thrombocytopenia | 1 | 2021 | 11 | 0.190 |
Why?
|
Cryopreservation | 1 | 2020 | 4 | 0.190 |
Why?
|
Severity of Illness Index | 1 | 2022 | 243 | 0.190 |
Why?
|
Hematologic Tests | 1 | 2020 | 11 | 0.180 |
Why?
|
Metabolism, Inborn Errors | 1 | 2020 | 1 | 0.180 |
Why?
|
Acyl-CoA Dehydrogenase | 1 | 2020 | 1 | 0.180 |
Why?
|
Glutaryl-CoA Dehydrogenase | 1 | 2020 | 1 | 0.180 |
Why?
|
UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2020 | 2 | 0.180 |
Why?
|
Molecular Epidemiology | 1 | 2020 | 44 | 0.180 |
Why?
|
Prothrombin | 1 | 2019 | 8 | 0.170 |
Why?
|
Pulmonary Embolism | 1 | 2019 | 7 | 0.170 |
Why?
|
Pregnancy Complications, Hematologic | 1 | 2019 | 9 | 0.170 |
Why?
|
Clinical Laboratory Services | 1 | 2019 | 4 | 0.170 |
Why?
|
Research | 2 | 1998 | 65 | 0.170 |
Why?
|
Limit of Detection | 1 | 2019 | 11 | 0.170 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 380 | 0.170 |
Why?
|
Linear Models | 1 | 2019 | 82 | 0.160 |
Why?
|
Smoking | 2 | 1996 | 99 | 0.160 |
Why?
|
Antithrombins | 1 | 2018 | 2 | 0.160 |
Why?
|
Centrifugation | 1 | 2018 | 2 | 0.160 |
Why?
|
Postpartum Period | 1 | 2019 | 78 | 0.160 |
Why?
|
Partial Thromboplastin Time | 1 | 2018 | 13 | 0.160 |
Why?
|
Mutation | 1 | 2019 | 299 | 0.160 |
Why?
|
Temperature | 1 | 2018 | 56 | 0.150 |
Why?
|
Virulence Factors | 1 | 2018 | 18 | 0.150 |
Why?
|
Ambulatory Care | 1 | 2018 | 54 | 0.150 |
Why?
|
Thyroid Diseases | 1 | 1997 | 1 | 0.150 |
Why?
|
Geriatrics | 1 | 1997 | 2 | 0.150 |
Why?
|
Thyrotropin | 1 | 1997 | 3 | 0.150 |
Why?
|
Postpartum Hemorrhage | 1 | 2019 | 69 | 0.150 |
Why?
|
Education, Medical, Undergraduate | 1 | 1997 | 6 | 0.150 |
Why?
|
Comorbidity | 1 | 2018 | 184 | 0.150 |
Why?
|
Mental Status Schedule | 1 | 1996 | 1 | 0.140 |
Why?
|
Pregnancy | 2 | 2019 | 1815 | 0.140 |
Why?
|
Thrombelastography | 2 | 2024 | 6 | 0.140 |
Why?
|
Students, Medical | 1 | 1996 | 14 | 0.140 |
Why?
|
Dementia | 1 | 1996 | 16 | 0.130 |
Why?
|
Alzheimer Disease | 1 | 1996 | 30 | 0.130 |
Why?
|
Infant | 2 | 2020 | 2145 | 0.130 |
Why?
|
Endothelial Cells | 2 | 2010 | 14 | 0.110 |
Why?
|
Child, Preschool | 1 | 2018 | 1675 | 0.110 |
Why?
|
Vena Cava Filters | 1 | 2013 | 4 | 0.110 |
Why?
|
Preoperative Care | 1 | 2013 | 8 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2013 | 20 | 0.110 |
Why?
|
Respiratory Function Tests | 2 | 1990 | 9 | 0.100 |
Why?
|
Adolescent | 3 | 2018 | 2858 | 0.100 |
Why?
|
Child | 1 | 2018 | 2180 | 0.100 |
Why?
|
Young Adult | 1 | 2018 | 2357 | 0.100 |
Why?
|
Lower Extremity | 1 | 2010 | 10 | 0.090 |
Why?
|
Atropine Derivatives | 1 | 1990 | 1 | 0.090 |
Why?
|
Ipratropium | 1 | 1990 | 2 | 0.090 |
Why?
|
Fenoterol | 1 | 1990 | 3 | 0.090 |
Why?
|
Blood Coagulation Disorders | 1 | 2009 | 6 | 0.090 |
Why?
|
Case-Control Studies | 2 | 2010 | 464 | 0.090 |
Why?
|
Reference Values | 4 | 2007 | 64 | 0.080 |
Why?
|
Workers' Compensation | 1 | 1988 | 5 | 0.080 |
Why?
|
Occupational Diseases | 1 | 1988 | 40 | 0.080 |
Why?
|
Pulmonary Fibrosis | 2 | 1987 | 9 | 0.080 |
Why?
|
Platelet Aggregation | 1 | 2007 | 12 | 0.080 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2007 | 12 | 0.080 |
Why?
|
Aspirin | 1 | 2007 | 15 | 0.080 |
Why?
|
HIV Seroprevalence | 1 | 2007 | 15 | 0.070 |
Why?
|
Vital Capacity | 3 | 1996 | 6 | 0.070 |
Why?
|
Forced Expiratory Volume | 3 | 1996 | 9 | 0.070 |
Why?
|
Air Travel | 1 | 2024 | 4 | 0.060 |
Why?
|
Oximetry | 1 | 2024 | 6 | 0.060 |
Why?
|
Healthy Volunteers | 1 | 2024 | 18 | 0.060 |
Why?
|
Socioeconomic Factors | 2 | 1996 | 405 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 2 | 1995 | 39 | 0.060 |
Why?
|
Drug Therapy, Combination | 3 | 2010 | 271 | 0.050 |
Why?
|
Anti-HIV Agents | 1 | 2009 | 1275 | 0.050 |
Why?
|
Lipid Metabolism, Inborn Errors | 1 | 2020 | 2 | 0.050 |
Why?
|
Sudden Infant Death | 1 | 2020 | 2 | 0.050 |
Why?
|
Genetic Carrier Screening | 1 | 2020 | 12 | 0.050 |
Why?
|
Genetic Loci | 1 | 2020 | 11 | 0.050 |
Why?
|
DNA | 1 | 2020 | 73 | 0.040 |
Why?
|
Regression Analysis | 2 | 1996 | 131 | 0.040 |
Why?
|
Anthropometry | 2 | 1996 | 101 | 0.040 |
Why?
|
Genotype | 1 | 2020 | 430 | 0.040 |
Why?
|
Flaviviridae | 1 | 1997 | 1 | 0.040 |
Why?
|
Hepatitis, Viral, Human | 1 | 1997 | 3 | 0.040 |
Why?
|
Thyroid Function Tests | 1 | 1997 | 1 | 0.040 |
Why?
|
Lung | 2 | 1996 | 70 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2018 | 367 | 0.040 |
Why?
|
Prospective Studies | 3 | 2010 | 1131 | 0.040 |
Why?
|
Plants, Toxic | 1 | 1996 | 2 | 0.030 |
Why?
|
Tobacco | 1 | 1996 | 14 | 0.030 |
Why?
|
Rural Population | 2 | 1997 | 624 | 0.030 |
Why?
|
Psychometrics | 1 | 1996 | 20 | 0.030 |
Why?
|
Radiography | 1 | 1996 | 80 | 0.030 |
Why?
|
Educational Status | 1 | 1996 | 68 | 0.030 |
Why?
|
Mass Screening | 2 | 1997 | 242 | 0.030 |
Why?
|
Cognition Disorders | 1 | 1996 | 35 | 0.030 |
Why?
|
Methylprednisolone | 1 | 1995 | 6 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2020 | 1410 | 0.030 |
Why?
|
Hydrocortisone | 1 | 1995 | 10 | 0.030 |
Why?
|
Pericardial Effusion | 1 | 1974 | 6 | 0.030 |
Why?
|
Primary Health Care | 1 | 1996 | 228 | 0.030 |
Why?
|
Acute Disease | 2 | 1995 | 105 | 0.030 |
Why?
|
Dabigatran | 1 | 2013 | 3 | 0.030 |
Why?
|
beta-Alanine | 1 | 2013 | 3 | 0.030 |
Why?
|
Morpholines | 1 | 2013 | 4 | 0.030 |
Why?
|
Thiophenes | 1 | 2013 | 4 | 0.030 |
Why?
|
Rivaroxaban | 1 | 2013 | 5 | 0.030 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2013 | 10 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2013 | 13 | 0.030 |
Why?
|
Drug Substitution | 1 | 2013 | 29 | 0.030 |
Why?
|
Chemoprevention | 1 | 2013 | 33 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 1997 | 1377 | 0.030 |
Why?
|
Disease Management | 1 | 2013 | 73 | 0.030 |
Why?
|
Risk Assessment | 1 | 2013 | 217 | 0.030 |
Why?
|
Chronic Disease | 1 | 1992 | 100 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2013 | 250 | 0.020 |
Why?
|
Protein S | 1 | 2010 | 3 | 0.020 |
Why?
|
Protein C | 1 | 2010 | 4 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 45 | 0.020 |
Why?
|
Ultrasonography | 1 | 2010 | 77 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 1990 | 112 | 0.020 |
Why?
|
Nebulizers and Vaporizers | 1 | 1990 | 2 | 0.020 |
Why?
|
Peak Expiratory Flow Rate | 1 | 1990 | 2 | 0.020 |
Why?
|
Random Allocation | 1 | 1990 | 23 | 0.020 |
Why?
|
Medicine in the Arts | 1 | 2009 | 3 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2010 | 409 | 0.020 |
Why?
|
Double-Blind Method | 1 | 1990 | 263 | 0.020 |
Why?
|
Tuberculosis, Pulmonary | 2 | 1987 | 320 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2010 | 654 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2007 | 64 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2007 | 25 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2010 | 867 | 0.020 |
Why?
|
Sarcoidosis | 1 | 1987 | 8 | 0.020 |
Why?
|
Lung Diseases | 1 | 1987 | 29 | 0.020 |
Why?
|
Viral Load | 1 | 2010 | 808 | 0.020 |
Why?
|
Prednisone | 1 | 1984 | 17 | 0.010 |
Why?
|
Prognosis | 1 | 1984 | 197 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 1987 | 63 | 0.010 |
Why?
|
Aminophylline | 1 | 1995 | 1 | 0.010 |
Why?
|
Albuterol | 1 | 1995 | 6 | 0.010 |
Why?
|
Bronchodilator Agents | 1 | 1995 | 7 | 0.010 |
Why?
|
Tuberculosis, Cardiovascular | 1 | 1974 | 1 | 0.010 |
Why?
|
Pericardium | 1 | 1974 | 2 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 1974 | 4 | 0.010 |
Why?
|
Cohort Studies | 1 | 1997 | 939 | 0.010 |
Why?
|
Urban Population | 1 | 1996 | 246 | 0.010 |
Why?
|
Bacteriuria | 1 | 1973 | 1 | 0.010 |
Why?
|
Tuberculosis, Urogenital | 1 | 1973 | 1 | 0.010 |
Why?
|
Pneumonia | 1 | 1974 | 127 | 0.010 |
Why?
|
Sulfonic Acids | 1 | 1971 | 3 | 0.010 |
Why?
|
Hydrochlorothiazide | 1 | 1971 | 9 | 0.010 |
Why?
|
Nocardia Infections | 1 | 1987 | 1 | 0.000 |
Why?
|
Dyspnea | 1 | 1987 | 9 | 0.000 |
Why?
|
Hypertension | 1 | 1971 | 397 | 0.000 |
Why?
|
Furans | 1 | 1971 | 4 | 0.000 |
Why?
|
Blood Urea Nitrogen | 1 | 1971 | 6 | 0.000 |
Why?
|
Placebos | 1 | 1971 | 44 | 0.000 |
Why?
|
Potassium | 1 | 1971 | 25 | 0.000 |
Why?
|
Sodium | 1 | 1971 | 26 | 0.000 |
Why?
|
Body Weight | 1 | 1971 | 110 | 0.000 |
Why?
|
Blood Pressure | 1 | 1971 | 312 | 0.000 |
Why?
|